| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/02/2005 | WO2005049029A1 Combination therapy comprising the use of et-743 and doxorubicin for treating cancer |
| 06/02/2005 | WO2005049014A1 Cox-2 inhibitors for the treatment or prevention of diabetes-related ocular disorders |
| 06/02/2005 | WO2005049013A1 Combinations of at1-antagonists, amiloride or triamterine, and a diuretic. |
| 06/02/2005 | WO2005049012A2 Tryptophan for use in promoting and maintaining abstinence |
| 06/02/2005 | WO2005049006A1 Remedy for diabetes |
| 06/02/2005 | WO2005048950A2 Tumor and infectious disease therapeutic compositions |
| 06/02/2005 | WO2005048946A2 Treatment for burn victims and animal carcasses |
| 06/02/2005 | WO2005048942A2 Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent |
| 06/02/2005 | WO2005048927A2 Methods and reagents for the treatment of inflammatory disorders |
| 06/02/2005 | WO2005048925A2 Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds |
| 06/02/2005 | WO2005048912A2 Methods and compositions for the treatment of helicobacter pylori-associated diseases using endoperoxide bridge-containing compounds |
| 06/02/2005 | WO2005048709A1 Use of panthenol in teat dip/spray preparations |
| 06/02/2005 | WO2005034979A3 Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| 06/02/2005 | WO2005034929A9 Tissue remodeling and vascularization |
| 06/02/2005 | WO2005032478A3 Treatment for diabetic microvascular and macrovascular complications |
| 06/02/2005 | WO2005028474A3 Pyrazoloquinoline derivatives as chk-1 inhibitors |
| 06/02/2005 | WO2005023270A3 Compositions and methods for use of antiviral drugs in the treatment of retroviral diseases resistant to nucleoside reverse transcriptase inhibitors |
| 06/02/2005 | WO2004034975A3 Sustained release profile modification |
| 06/02/2005 | WO2003075847A3 NOVEL CURCUMINOID-FACTOR VIIa CONSTRUCTS AS SUPPRESSORS OF TUMOR GROWTH AND ANGIOGENESIS |
| 06/02/2005 | WO2003059253A3 Compositions and methods for altering glucose production |
| 06/02/2005 | US20050119552 Methods and systems for assessing biological material using optical detection techniques |
| 06/02/2005 | US20050119484 Mitotic kinesin inhibitors |
| 06/02/2005 | US20050119482 Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors |
| 06/02/2005 | US20050119458 Transport protein for use in identifying modulator for prevention and treatment of cell proliferative, skin and psychological disorders; anticonvulsants; insecticides; pesticides; anthelmintics |
| 06/02/2005 | US20050119457 Human proteins |
| 06/02/2005 | US20050119352 Administration of a cell cycle checkpoint activator eg beta -lapachone or its derivative combined with an oncogenic kinase modulator eg imatinib |
| 06/02/2005 | US20050119345 2-Amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives; effective for treating and preventing psychiatric disorders such as schizophrenia, anxiety, bipolar disorder and epilepsy, neurological diseases such as drug dependence, Alzheimer's disease, Huntington's chorea |
| 06/02/2005 | US20050119338 Combination of cytochome p450 dependent protease inhibitors |
| 06/02/2005 | US20050119337 Methods of application of Schisandrin B in the preparation of anticancer medications |
| 06/02/2005 | US20050119323 Hormone sensitive vcancer; antiproliferative agents ; induction apoptosis; angiotensin inhibitors |
| 06/02/2005 | US20050119314 Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent |
| 06/02/2005 | US20050119310 nucleoside / nucleitide antiviral agents [2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC)]; immunomodulators / immunostimulants; synergistic effect; prevent drug resistance; reduce toxicity |
| 06/02/2005 | US20050119303 kit; N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide; VEGF (endothelial growth factor)and FGF (fibroblast growth factor) receptor kinase inhibitors or antibody; integrin inhibitor; synergistic |
| 06/02/2005 | US20050119299 Ophthalmic solutions containing tetrazole derivatives |
| 06/02/2005 | US20050119297 Use of 5HT3 agonists for relaxing the fundus |
| 06/02/2005 | US20050119289 Synergistic mixture; anticancer agents; therapy for skin cancer; adenosine receptor antagonist |
| 06/02/2005 | US20050119286 Beta-2'-or 3'-halonucleosides |
| 06/02/2005 | US20050119277 Benzazole derivatives for the treatment of scleroderma |
| 06/02/2005 | US20050119272 amplify the effect of nitric oxide on skeletal muscle insulin-mediated glucose uptake; antidiabetic agents |
| 06/02/2005 | US20050119262 Synergistic mixture for vision disorders |
| 06/02/2005 | US20050119259 Synergistic mixture of anticoagulant and antiarrhythmia agents |
| 06/02/2005 | US20050119250 Amino-derivatives as novel inhibitors of histone deacetylase |
| 06/02/2005 | US20050119246 2-(4-{[1-(2,2-dimethylpropanoyl)-4-piperidinyl]methyl}-3,5-dimethyl-1H-pyrazol-1-yl)-1-methylethylcarbamate; appetite suppressants; obesity, diabetes, feeding behavior, bulimia, anorexia nervosa and premenstrual tension; side effect reduction |
| 06/02/2005 | US20050119239 Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and an active substance which influences prostaglandin metabolism |
| 06/02/2005 | US20050119228 Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof |
| 06/02/2005 | US20050119223 Injectable solution containing a shark-derived chondroitin sulfate iron colloid |
| 06/02/2005 | US20050119218 Multiple antioxidant micronutrients |
| 06/02/2005 | US20050119217 Methods and reagents for the treatment of proliferative diseases |
| 06/02/2005 | US20050119216 Pharmaceutical compositions and methods relating to fucans |
| 06/02/2005 | US20050119207 Administering an agents, such as antibody,which prevents gene expresion; analgesics; anesthetics |
| 06/02/2005 | US20050119201 Inhibitor of dna methylation |
| 06/02/2005 | US20050119196 Remedies for lung cancer |
| 06/02/2005 | US20050119188 Method of treating breast cancer |
| 06/02/2005 | US20050119160 Administering pyrimidopyrimidine compound such as dipyridamole with methotrexate or aspirin |
| 06/02/2005 | US20050118715 Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| 06/02/2005 | US20050118696 Methods and means for modulating PGE synthase activity |
| 06/02/2005 | US20050118694 Culturing microorganism under aerobic conditions and generating preferential biopolymer particle; nutraceuticals; vitamins |
| 06/02/2005 | US20050118656 Methods for diagnosis and treatment of epithelial-derived cancers |
| 06/02/2005 | US20050118586 Expression vector comprising nucleotide sequences coding heterologous polypeptide for use in forensic analysis as chromosome, tissue, cell and organelle specific markers |
| 06/02/2005 | US20050118585 Using allelic variation in bone morphogenic signaling family proteins as diagnostic tool in detection of vision defcets |
| 06/02/2005 | US20050118579 Using allelic variation in canalicular multispecific organic anion transporter (cMOAT) gene as diagnostic tool in detection of liver and bile duct disorders |
| 06/02/2005 | US20050118562 Methods for minimizing spasticity in blood vessel grafts |
| 06/02/2005 | US20050118420 Method for configuring air-core photonic-bandgap fibers free of surface modes |
| 06/02/2005 | US20050118279 Mineral, nutritional, cosmetic, pharmaceutical, and agricultural compositions and methods for producing the same |
| 06/02/2005 | US20050118271 Polytartrate composition |
| 06/02/2005 | US20050118263 Composition |
| 06/02/2005 | US20050118256 Extended release alpha-2 agonist pharmaceutical dosage forms |
| 06/02/2005 | US20050118253 comprising a nucleic acid that is fully encapsulated within a lipid; for treating a neoplasia in a mammal |
| 06/02/2005 | US20050118236 composite scaffolds which are viable for tissue engineering of cartilage in vitro and transplanting the cartilage to a defect; bioactive, flexible, bioactive glass weaves and scaffolds with high porosity |
| 06/02/2005 | US20050118230 Methods and compositions for regenerating connective tissue |
| 06/02/2005 | US20050118221 Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound |
| 06/02/2005 | US20050118187 Combinations and methods for treating neoplasms |
| 06/02/2005 | US20050118180 Synergistic mixture with an alkylating agent, antibiotic agent, antimetabolic agent, hormonal agent, plant-derived agent, anti-angiogenesis agent and/or a biologic agent |
| 06/02/2005 | US20050118168 Administering a compound which binds to a C-type lectin on the surface of a dendritic cell, with the proviso that the C-type lectin is not the DEC-205 receptor |
| 06/02/2005 | US20050118162 Treatment of micro-organism infection |
| 06/02/2005 | US20050118157 Treatment of central nervous system damage |
| 06/02/2005 | US20050118150 Population of hematopoietic cells, made to exhibit a greater clonogenic potential, engraftment potential, immune system reconstitution potential and/or proportion of CD34+ positive cells by culturing with a transition metal compound that chelates copper such as tetraethylenepentamine |
| 06/02/2005 | US20050118147 Cotransplanting stem cells from multiple stem cell sources such as bone marrow, peripheral blood, or umbilical cord blood; suppressing graft versus host disease |
| 06/02/2005 | US20050118145 Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants |
| 06/02/2005 | US20050118142 Stem cells are from a syngeneic, allogeneic or xenogeneic donor; the composition of donor CD34+ hematopoietic cells in combination with donor alpha beta TCR+ T-cells reduces the risk of Graft Versus Host Disease by half |
| 06/02/2005 | DE10352602A1 Kosmetisches oder therapeutisches Kombinationspräparat Cosmetic or therapeutic combination product |
| 06/02/2005 | CA2546210A1 Methods and compositions for the treatment of helicobacter pylori-associated diseases using endoperoxide bridge-containing compounds |
| 06/02/2005 | CA2546019A1 Therapeutic peg solution concentrate |
| 06/02/2005 | CA2545615A1 Methods and reagents for the treatment of inflammatory disorders |
| 06/02/2005 | CA2545514A1 Combination of a dpp iv inhibitor and an antiobesity or appetite regulating agent |
| 06/02/2005 | CA2545054A1 Combination therapy comprising the use of et-743 and paclitaxel for treating cancer |
| 06/02/2005 | CA2545043A1 Combination therapy comprising the use of et-743 and doxorubicin for treating cancer |
| 06/02/2005 | CA2544230A1 Combinations of at1-antagonists, amiloride or triamterine, and a diuretic |
| 06/02/2005 | CA2541293A1 Combinations comprising ampa receptor antagonists for the treatment of schizophrenia |
| 06/02/2005 | CA2537300A1 Treatment of asprin resistance with radix salviae miltiorrhizae, its extract and composition |
| 06/01/2005 | EP1536234A2 Soluble CTLA4 mutant molecules and uses thereof |
| 06/01/2005 | EP1536010A1 Preventives/remedies for cancer |
| 06/01/2005 | EP1535630A1 Preventive for the onset of diabetes |
| 06/01/2005 | EP1535629A1 Drugs for improving the prognosis of brain injury and a method of screening the same |
| 06/01/2005 | EP1535617A1 Remedy or preventive for keratoconjunctival epithelial cell injury |
| 06/01/2005 | EP1535614A2 Materials and methods for detection and treatment of immune system dysfunctions |
| 06/01/2005 | EP1535067A2 PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE |
| 06/01/2005 | EP1534827A1 Method for generating monoclonal antibodies |
| 06/01/2005 | EP1534695A2 Tyrosine kinase inhibitors |
| 06/01/2005 | EP1534512A1 Coated particles, methods of making and using |